Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Pharvaris NV PHVS

Healthcare Biotechnology
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist for the treatment of attacks due to bradykinin-mediated angioedema, including hereditary... see more

Current News (NDAQ:PHVS)

Pharvaris Outlines 2026 Strategic Priorities

GlobeNewswire January 12, 2026

Pharvaris Announces Positive Topline Data from RAPIDe-3 Pivotal Study Confirming Potential of Deucrictibant for On-Demand Treatment of HAE Attacks

GlobeNewswire December 3, 2025

Pharvaris Reports Third Quarter 2025 Financial Results and Provides Business Update

GlobeNewswire November 12, 2025

Data Supporting the Potentially Differentiated Pharvaris Portfolio Presented at ACAAI 2025 Annual Scientific Meeting

GlobeNewswire November 10, 2025

Pharvaris to Present Clinical Data at the ACAAI 2025 Annual Scientific Meeting

GlobeNewswire October 23, 2025

Pharvaris Reports Second Quarter 2025 Financial Results and Provides Business Update

GlobeNewswire August 12, 2025

Pharvaris Announces Closing of $201.2 Million Upsized Public Offering of Ordinary Shares and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares

GlobeNewswire July 24, 2025

Pharvaris Announces Pricing of Upsized $175 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

GlobeNewswire July 22, 2025

Pharvaris Announces Proposed Public Offering of Ordinary Shares

GlobeNewswire July 22, 2025
View More News ››

Opinion & Analysis (NDAQ:PHVS)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:PHVS)

Be the first to post on this bullboard.

LaFleur Minerals Inc.

LaFleur Minerals Inc.

LaFleur Minerals Inc. explores for lithium and gold deposits in Canada. The company holds interest in the Swanson Gold ...
View More »

Podcasts